Dr. Martens plc (DOCS), the iconic British footwear brand listed on the London Stock Exchange and a constituent of the FTSE 250, has reported first half results for the 26 weeks ended 27 September 2026, revealing group revenue of £290.4m, down 9.2% on a constant currency basis. The decline was driven primarily by weakness in its core boots category, which the company attributes to exceptionally hot summer weather and ongoing challenging market conditions. Chief Executive Ije Nwokorie described the H1 performance as "disappointing", whilst pointing to resilience in shoes and sandals and early positive consumer engagement with the new 'With Bouncing Soles' brand platform.

Key Points

  • Dr. Martens plc (DOCS) — FTSE 250-listed British footwear brand founded in Northamptonshire
  • Group revenue fell to £290.4m in H1 FY27, down 9.2% on a constant currency basis versus £322.0m in H1 FY26
  • Adjusted PBT loss of £13.1m (constant currency); gross margin steady at 65.3%; interim dividend of 0.85p declared
  • Investors will be watching peak trading across Black Friday, Christmas, and post-Christmas periods, which the company says are crucial to the full year outcome

Boots Revenue Falls 20% as Hot Summer and DTC Changes Weigh on H1 FY27 Performance

Boots, historically Dr. Martens' dominant category, saw revenue decline 20% in the period, falling to represent 44% of H1 revenue compared with 49% in H1 FY26. The company states the decline was accelerated by the exceptionally hot summer, which suppressed demand across European markets in particular. UK revenue fell 21.3% on a constant currency basis, described as below the company's own plans, while DACH and Japan were broadly flat year-on-year. The DTC-to-B2B revenue mix stood at 54%:46%, with B2B outperforming DTC as expected. Shoes grew 1% year-on-year to represent 41% of revenue, and sandals grew 5%, partly aided by the same warm conditions that hurt boots.

Gross Margin Holds at 65.3% Amid Cost Discipline and New Ecommerce Platform Launch

Despite the revenue decline, Dr. Martens maintained gross margin at 65.3%, with the company noting good cost of goods sold control and average selling price performance offsetting channel mix pressures. The announcement also discloses a reclassification of retail outbound freight costs from operating expenditure into cost of sales from FY27, with the prior year not restated; excluding this change, gross margin would have been 66.1%. Other operating costs fell 8.6% on a constant currency basis. Marketing costs increased by £3.0m on a constant currency basis as the company prepared to launch its new global brand platform and a rebuilt ecommerce site across the US and major European markets.

New Brand Centres Open in Paris, Munich and New York as Retail Strategy Takes Shape

The company reports that the first wave of upgraded Brand Centres opened in Paris (Le Marais), Munich (Sendlinger Street) and New York (Herald Square) in recent weeks, with Los Angeles (Century City) set to open imminently. The company states that early consumer reaction has been encouraging, with significant average transaction value growth compared with comparable local stores, and a meaningful outperformance in bags and accessories revenue mix. Dr. Martens operates across more than 60 countries and employs around 3,600 people. The company plans to invest in around 30 high-potential stores over the next 18 months, focused on elevating them into Brand Centres.

Wide Range of Full Year Outcomes Flagged as Peak Trading Period Proves Decisive

The company cautions that there is a wide range of possible outcomes in both revenue and profit before tax terms for the full year, with November, December, and early January identified as crucial trading months. Sell-side revenue consensus as of 11 November 2026 stood at £777m, with a range of £763m to £790m; adjusted PBT consensus was £65.7m, ranging from £61.9m to £71.8m. Net debt including leases stood at £310.8m at the period end. The company's medium-term guidance remains unchanged, targeting sustainable profitable revenue growth and a mid to high-teens EBIT margin, though the near-term outlook is explicitly dependent on peak trading execution.